PRISM BioLab is pleased to announce that our President and CEO, Dai Takehara, will speak at the LINK-J symposium “Drug Discovery Frontier 2026.” This symposium will cover cutting-edge topics including the science of sleep and medical approaches, TPD (Targeted Protein Degradation inducers), RI pharmaceuticals, peptide-mimetic compounds, gene editing technology, and iPSC cell therapy. Takehara will...

PRISM BioLab today announced that the abstract titled “Leveraging E7386 phase 1 trials for cardiac safety: gaining concentration-QTc insights to inform early-stage oncology development” is now available. E7386 is a molecule jointly created by PRISM BioLab and Eisai Co., Ltd. The results will be published as an ASCO Online Publication by Eisai at the American...

PRISM BioLab announces that our President and CEO, Dai Takehara, will participate as a speaker at the Radio NIKKEI Japan Tour “Bio IR & Hideaki Sakurai Stock Seminar in Osaka,” to be held on Saturday, June 13, 2026. The seminar details are provided below. We look forward to your participation. For more details, please click...

PRISM BioLab announces that the research and license agreement between PRISM BioLab and Boehringer Ingelheim International GmbH has expired upon completion of its contractual term. For more details, please click here (English language PDF).

PRISM BioLab announces that we have received a Notice of Allowance for a patent on PepMetics® technology library compounds in the United States. For more details, please click here (Japanese language PDF).

PRISM BioLab announces that Eisai Co., Ltd. will present preclinical research results for E7386, co-created by PRISM BioLab and Eisai, in combination with lenvatinib mesylate, at the American Association for Cancer Research (AACR) Annual Meeting 2026 from April 17 to 22, 2026. The abstract of the study has been disclosed. For more details, please click...

PRISM BioLab and Receptor.AI today announced that they have entered into a drug discovery collaboration agreement to develop an integrated, AI-navigated, physics-guided platform for the discovery of orally available small molecules targeting intracellular protein–protein interactions (PPIs), membrane proteins, and complex receptor systems. For more details, please click here.

PRISM BioLab announces that a paper reporting the results of a domestic Phase I clinical trial on E7386, jointly created with Eisai Co., Ltd. has been published in the ESMO OPEN, the open access medical journal issued by the European Society for Medical Oncology (ESMO). For more details, please click here.

We would like to inform you that PRISM BioLab will relocate our Tokyo office to the address below, effective January 19, 2026. Please note that our main phone number will remain unchanged. Relocation Date: January 19, 2026 New Address: Nihonbashi Life Science Building 2, Room 401 3-11-5 Nihonbashi-Honcho, Chuo-ku Tokyo 103-0023, Japan Phone: +81-466-53-8383 (Main)...

PRISM BioLab and Talus Bioscience, Inc. are pleased to announce that we have entered into a joint research agreement to discover novel inhibitors targeting transcription factors and protein-protein interactions (PPIs). For more details, please click here.